Mylan appoints a global commercial lead for OTC business
pharmafile | November 3, 2015 | Appointment | Manufacturing and Production |Â Â Mylan, OTC, Ranjan Ray Chaudhuri, over the counterÂ
Mylan has appointed Ranjan Ray Chaudhuri as its new global commercial lead for the company’s over-the-counter (OTC) business. Chaudhuri will report to Rajiv Malik, the president of Mylan.
Chaudhuri joins Mylan from GlaxoSmithKline consumer healthcare, where he served for nearly three decades. During his time at GSK, Chaudhuri was responsible for the company’s global smoking reduction and cessation category, which included NiQuitin and its other nicotine replacement therapies, and delivered double-digit revenue growth.
In addition, Chaudhuri led the development of an innovative program designed to improve the quality of life of COPD patients with other GSK respiratory products, such as Advair and Seretide fluticasone and salmeterol). He also recently led the divestiture of an OTC portfolio to Perrigo, a move prompted by GSK’s formation of a consumer healthcare joint venture with Novartis.
Mylan chief executive Heather Bresch comments: “We are committed to investing significantly to expand our OTC business, knowing that OTC is an important channel that will complement our existing strengths in the prescription and generic channels around the world.”
Mylan president Rajiv Malik says: “Ranjan joins us at an opportune time, bringing deep knowledge of the OTC space, sales and marketing leadership, experience in developed and emerging markets, and a proven track record for delivering results. He will work closely with me and my colleagues at the global level, as well as others, within both Mylan’s and Perrigo’s commercial structures, to further realise the combination’s commercial value should we complete the Perrigo transaction.”
Chaudhuri says: “I have been watching Mylan’s growth and performance for some time, and am extremely impressed with the calibre of its leaders, the strength of its brand, and its global team’s ability to consistently perform and create value both organically and through strategic initiatives
“The opportunity to build upon Mylan’s one-of-a-kind global platform and contribute to the organisation’s ongoing evolution is tremendously exciting to me. I look forward to bringing to Mylan all that I have learned over the years to help further distinguish it as one of the world’s great companies.”
Related Content
Arcturus Therapeutics provides update on OTC deficiency and CF programmes
Arcturus Therapeutics has announced mid-year updates for ARCT-810, an investigational mRNA therapeutic to treat ornithine …
FDA approves a second OTC naloxone nasal spray
The US Food and Drug Administration (FDA) has announced that it has approved RiVive, 3mg …
FDA approves first OTC daily oral contraceptive pill
The US Food and Drug Administration (FDA) has announced that it has approved the Opill …
